Lexaria Bioscience: Taking Aim at the $28 Billion Hypertension Market; Human Clinical Study Yields ‘Remarkable’ Results

New York, New York–(Newsfile Corp. – September 20, 2022) – PCG Digital – Lexaria Bioscience (NASDAQ: LEXX) (NASDAQ: LEXXW) is targeting the $28 billion hypertension drug market with its innovative drug delivery platform. Its proprietary therapeutic, DehydraTECH-CBD, offers an alternative to traditional cannabidiol (CBD) dosing methods, enabling improved and more rapid absorption of drugs into the bloodstream and brain.

There is currently only one FDA approved CBD drug available on the market, used to treat pediatric epilepsy. Lexaria is positioned to potentially deliver the second-ever FDA approved CBD therapeutic, which has the potential to be life-changing for those living with hypertension.

Hypertension is a serious public health issue. Over 116 million Americans, and more than a billion adults worldwide, are living with high blood pressure, a major cause of premature death. However, as hypertension diagnosis numbers continue to climb, there has been a marked slowing of research and development for novel hypertension drugs.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/137710